a significant trendp = 0.01
In patients with zero, one, two, or three baseline panel abnormalities, there was a significant trend toward EA risk reduction among NSAID users compared to nonusers ( p = 0.01).
In patients with zero, one, two, or three baseline panel abnormalities, there was a significant trend toward EA risk reduction among NSAID users compared to nonusers ( p = 0.01).
NSAID users with two baseline abnormalities had a significant or marginally significant increased cancer incidence relative to NSAID users with zero or one abnormality ( p = 0.013 and p = 0.07, respectively).
Although TP53 mutation was highly significant in univariate analysis, it became nonsignificant for EA risk prediction when 17p LOH was included in the model.